Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of majo…
Biotechnology
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -73.09 | -52.45 | -30.30 | |
| Graham Fair Price | -27.81 | 9.93 | 13.76 | |
| PEG | 161.58 | 0.43 | -0.17 | |
| Price/Book | 28.43 | 25.33 | 19.72 | |
| Price/Cash Flow | 45.08 | -68.12 | -124.04 | |
| Prices/Earnings | -39.79 | -13.34 | -9.55 | |
| Price/Sales | -7.62 | 48.65 | 52.66 | |
| Price/FCF | 45.08 | -68.12 | -124.04 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -0.58 | 0.89 | 0.90 | |
| Operating Margin | 33.23 | -0.92 | -1.37 | |
| ROA | 25.31 | -0.13 | -0.17 | |
| ROE | -0.52 | -0.47 | 8.13 | |
| ROIC | -0.26 | -0.21 | 17.09 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.02 | < 0.005 | 281.92 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.58 | 0.30 | -48.24 | |
| EPS QOQ | -0.58 | 0.31 | -46.56 | |
| FCF QOQ | 0.44 | -0.76 | 74.88 | |
| Revenue QOQ | 0.24 | 0.05 | -79.59 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 184.62 | 172.55 | -6.54 | |
| Days Sales Outstanding (DSO) | 119.30 | 121.72 | 2.03 | |
| Inventory Turnover | 0.49 | 0.52 | 7.00 | |
| Debt/Capitalization | 0.48 | 0.56 | 14.84 | |
| Quick Ratio | 3.46 | 3.01 | -13.25 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 4.04 | 3.04 | -24.68 | |
| Cash | 8.16 | 6.99 | -14.29 | |
| Capex | < 0.005 | < 0.005 | -1298.12 | |
| Free Cash Flow | -0.64 | -1.13 | -76.14 | |
| Revenue | 1.51 | 1.58 | 4.71 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad